Clinical trial

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed

Key facts

NCT number NCT00444457
Title Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants
Official title A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States
Lead sponsor Wyeth is now a wholly owned subsidiary of Pfizer, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Vaccines, Pneumococcal
Intervention type Biological
Interventions 13-valent Pneumococcal Conjugate Vaccine, 7vPnC
Enrollment 1,712
Start date May 1, 2007
Primary completion Jun 1, 2009
Completion Jun 1, 2009
First posted Mar 7, 2007
Last update posted Oct 15, 2012
Countries United States

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies